Contribute Try STAT+ Today

In the world of digital health, money is flying around like never before.

All that cash is driving dealmaking that will shape the future of the sector. Enthusiastic investors angling to get in on the virtual care boom brought on by the Covid-19 pandemic have propped up sky-high valuations. Companies hoping to capitalize on their first-mover advantages are scooping up complementary businesses in an effort to assemble category winners. The SPAC craze has found many willing targets among emerging companies that hope to one day turn a profit but are ready to go public now.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment